Mr. Jeffrey Hackman reports

FENNEC PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM WITH THREE KEY APPOINTMENTS TO ACCELERATE THE COMPANY'S NEXT STAGE OF GROWTH

Fennec Pharmaceuticals Inc. has strengthened its executive leadership team with the appointments of Dr. Pierre S. Sayad, PhD, MS, as chief medical officer, Terry Evans as chief commercial officer and Christiana Cioffi, MBA, as chief strategy officer, all of which become effective immediately.

"Building an experienced, multitalented executive leadership team is a critical step for Fennec as we embark on a new chapter in the organization's evolution, and I am delighted to welcome Pierre, Terry and Christiana to Fennec," said Jeffrey S. Hackman, chief executive officer and director of Fennec Pharmaceuticals. "Pierre, Terry and Christiana are seasoned biopharmaceutical industry executives with proven clinical, commercial, operational and oncology market expertise. We believe that their leadership, combined with Fennec's talented employee base, will significantly accelerate our ability to build upon and seamlessly execute our commercialization strategy for Pedmark, the first and only therapy approved in the U.S. and Europe to reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment."

Dr. Sayad is an accomplished biopharmaceutical executive with more than 22 years of proven success building and leading world-class organizations. During his tenure in the industry, Dr. Sayad has launched nine novel drugs across 14 therapeutic areas, including oncology (both solid tumours and hematologic malignancies) and neuroscience (depression, schizophrenia, bipolar and ADHD (attention-deficit hyperactivity disorder)). Trained as a molecular physiologist, Dr. Sayad has been heavily involved in the successful commercial launches of several drugs, including oncology drugs at Onyx Pharmaceuticals, Karyopharm Therapeutics, Oncopeptides and CTI Biopharma with Kyprolis, Xpovio, Pepaxto and Vonjo, respectively, and Eli Lilly and Co.'s blockbuster neuroscience drugs Zyprexa, Cymbalta and Strattera. He also served as senior vice-president, business development and global medical affairs, at the International Myeloma Foundation. Earlier in his career, Dr. Sayad was a strategic management consultant for Campbell Alliance, a specialized consulting firm focused in the biotech and pharmaceutical industries. Prior to his appointment at Fennec, Dr. Sayad served as chief operating officer and interim chief medical officer at Zephyr Labz. Dr. Sayad is a graduate of the School of Medicine, Loma Linda University, as well as Harvard Business School.

As a seasoned commercial and operations leader in the pharmaceutical industry, Mr. Evans is an adept executive known for delivering significant revenue growth and leading high-performing teams. Mr. Evans's industry experience spans all facets of commercial operations, including sales, sales management, operations, market access, trade, specialty pharmacy and data analytics. In his more than 25 years of experience with companies, including Currax Pharmaceuticals, Horizon Therapeutics, Graceway Pharmaceuticals and Medicis, he has driven substantial results by executing strategic initiatives for revenue generation and improved patient access to innovative therapies, including Duexis, Pennsaid 2 per cent, Actimmune, Krystexxa and Procysbi. Known for this patient-centred approach, Mr. Evans has been particularly focused on pharmaceutical start-ups developing strategies for successful market entry, maximizing access and commercial performance. Prior to his appointment at Fennec, Mr. Evans was chief executive officer of Unite Pharma Trade Advisors.

Ms. Cioffi brings more than 20 years of collective and demonstrated excellence in strategy, leadership and culture building, inclusive of a 13-year proven record of developing award-winning, disruptive strategies and launch excellence from early-stage through life-cycle management phases with leading biopharmaceutical companies. As a recipient of multiple industry marketing awards, Ms. Cioffi has focused primarily in oncology, rare disease and hematology therapeutic areas at companies, including Shield Therapeutics, Stemline Therapeutics, EUSA Pharma, Karyopharm Therapeutics, Servier (previously Shire/Baxalta/Baxter) and Abbott Laboratories. During her tenure in the industry, Ms. Cioffi has led commercial and marketing strategy for several oncology and rare disease brands, including Qarziba, Oncaspar Liquid, Oncaspar Lyo, Cal-PEG, Sylvant, Xpovio and Elzonris. Prior to her appointment at Fennec, Ms. Cioffi served as a strategic adviser and leadership coach at Disruptify Consulting. Ms. Cioffi is a decorated army veteran and a Bronze Star recipient, with proven and outstanding leadership skills while leading soldiers in combat and two deployments during Operation Iraqi Freedom.

"On behalf of the board of directors, we are confident in the significant industry, oncology market and leadership expertise that Pierre, Terry and Christiana bring to Fennec. We look forward to working closely with them, along with Jeff, our recently appointed chief executive officer, to continue making a meaningful difference in the lives of pediatric patients and, consistent with our NCCN [National Comprehensive Cancer Network] recommendation, adolescent and young adult (AYA) cancer patients through the availability of Pedmark while creating value for our shareholders," said Dr. Khalid Islam, chairman of Fennec Pharmaceuticals.

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of Pedmark to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, Pedmark received U.S. Food and Drug Administration approval in September, 2022, and European Commission approval in June, 2023, and United Kingdom approval in October, 2023, under the brand name Pedmarqsi. Pedmark has received orphan drug exclusivity in the United States and Pedmarqsi has received pediatric use marketing authorization in Europe, which includes eight years plus two years of data and market protection.

We seek Safe Harbor.